Download this free whitepaper to learn more.
Real-world evidence (RWE) has become indispensable across the drug development lifecycle, from early research through market access. While the field has made significant progress addressing methodological and data-related limitations, biopharma companies continue to face persistent challenges related to data quality, completeness and integration. To unlock the full potential of RWE, the industry is increasingly turning to payer-sourced data, which offers comprehensive visibility across care settings, improved data provenance and confidence in accuracy and reliability.
This paper explores how payer-derived datasets—integrating claims, clinical, laboratory and patient-reported data—can accelerate research and development timelines, enhance regulatory readiness and strengthen value demonstration for market access. Drawing insights from experts at Geron and Carelon Research, it highlights best practices for overcoming confounding and bias, ensuring transparency and traceability, and leveraging advanced analytics and artificial intelligence to scale evidence generation. The analysis underscores that strategic partnerships with experienced RWE providers are essential for transforming complex real-world data into actionable insights that meet regulatory standards and payer expectations.
Offered Free by: Carelon Research
See All Resources from: Carelon Research
